ICCC
ImmuCell Corporation
Price Chart
Latest Quote
$9.79
-0.08 (-0.76%)
Current Price
| Previous Close | $9.87 |
| Open | $9.97 |
| Day High | $10.10 |
| Day Low | $9.61 |
| Volume | 38,835 |
Stock Information
| Shares Outstanding | 9.05M |
| Total Debt | $12.78M |
| Cash Equivalents | $6.81M |
| Revenue | $29.93M |
| Net Income | $-545K |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $88.57M |
| EPS (TTM) | $-0.07 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $94.53M |
| Sales | $29.93M |
| Income | $-545K |
| Book/sh | $3.22 |
| Cash/sh | $0.75 |
| Employees | 73 |
Financial Ratios
| Quick Ratio | 2.44 |
| Current Ratio | 4.82 |
| Debt/Eq | 43.86 |
| EPS Growth TTM | 34.20% |
Returns & Margins
| ROA | 4.60% |
| ROE | -1.88% |
| Gross Margin | 42.59% |
| Operating Margin | 19.01% |
| Profit Margin | -1.82% |
Ownership
| Insider Ownership | 32.13% |
| Institutional Ownership | 21.70% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -89.00 |
| P/S | 2.96 |
| P/B | 3.04 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $9.78 |
| SMA50 | $9.09 |
| SMA200 | $6.89 |
| RSI | 42.35 |
| ATR | 0.3443 |
| Shares Float | 6.00M |
| Short Float | 0.12% |
| Short Ratio | 0.27 |
| Volatility | 0.56 |
| Rel Volume | 1.58 |
Performance History
| Week | +4.37% |
| Month | -3.26% |
| Quarter | +53.21% |
| 6 Months | +63.99% |
| YTD | +65.37% |
| Year | +47.22% |
| 3 Years | +63.71% |
| 5 Years | -5.04% |
| 10 Years | +35.41% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $9.79 | 38,800 |
| 2026-06-23 | $9.87 | 29,400 |
| 2026-06-22 | $9.75 | 58,900 |
| 2026-06-18 | $9.49 | 34,200 |
| 2026-06-17 | $9.39 | 29,400 |
| 2026-06-16 | $9.38 | 14,100 |
| 2026-06-15 | $9.53 | 9,700 |
| 2026-06-12 | $9.68 | 9,400 |
| 2026-06-11 | $9.74 | 10,900 |
| 2026-06-10 | $9.67 | 32,400 |
| 2026-06-09 | $9.77 | 18,000 |
| 2026-06-08 | $9.70 | 20,800 |
| 2026-06-05 | $9.61 | 12,500 |
| 2026-06-04 | $9.87 | 8,700 |
| 2026-06-03 | $10.05 | 15,800 |
| 2026-06-02 | $9.79 | 39,900 |
| 2026-06-01 | $9.67 | 17,500 |
| 2026-05-29 | $10.24 | 29,800 |
| 2026-05-28 | $9.90 | 38,400 |
| 2026-05-27 | $10.63 | 21,400 |
| 2026-05-26 | $10.50 | 66,700 |
About ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.
đ° Latest News
ICCC's Valuation Remains Premium: Is it Worth Overpaying for?
Zacks âĸ 2026-06-18T14:26:00Z
ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand
Zacks âĸ 2026-05-25T13:45:00Z
ImmuCell Corp (ICCC) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth
GuruFocus.com âĸ 2026-05-15T23:01:23ZImmuCell Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-15T15:06:24Z
Hereâs Why ImmuCell Corporation (ICCC) is Emerging as an Intriguing Micro-Cap Opportunity
Insider Monkey âĸ 2026-05-13T08:18:49Z
The Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCell
Zacks âĸ 2026-04-22T07:59:00Z
Top Stock Reports for Goldman Sachs, NextEra Energy & Shopify
Zacks âĸ 2026-04-21T20:17:00Z
ImmuCell Corp (ICCC) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges
GuruFocus.com âĸ 2026-03-07T01:02:50ZImmuCell 2025 Net Loss Narrows Y/Y as Sales & Margins Improve
Zacks âĸ 2026-03-06T17:43:00Z
ImmuCell Q4 Earnings Call Highlights
MarketBeat âĸ 2026-03-06T02:07:49Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $16,198,971 | $18,552,125 | $13,602,385 | $10,919,183 |
| Cost Of Revenue | $16,198,971 | $18,552,125 | $13,602,385 | $10,919,183 |
| Total Revenue | $27,644,174 | $26,493,169 | $17,471,669 | $18,567,962 |
| Operating Revenue | $27,644,174 | $26,493,169 | $17,471,669 | $18,567,962 |
| Expenses | ||||
| Interest Expense | $439,036 | $526,059 | $452,979 | $348,536 |
| Total Expenses | $25,994,869 | $28,133,328 | $23,219,747 | $20,866,905 |
| Other Income Expense | $-2,343,087 | $-15,391 | $357,135 | $8,246 |
| Other Non Operating Income Expenses | $3,776 | - | $107 | $912 |
| Net Non Operating Interest Income Expense | $-334,675 | $-491,023 | $-379,028 | $-195,436 |
| Total Other Finance Cost | $54,348 | $42,666 | $22,619 | $7,658 |
| Interest Expense Non Operating | $439,036 | $526,059 | $452,979 | $348,536 |
| Operating Expense | $9,795,898 | $9,581,203 | $9,617,362 | $9,947,722 |
| Selling And Marketing Expense | $3,553,375 | $3,466,072 | $3,088,215 | $3,190,033 |
| General And Administrative Expense | $3,200,643 | $2,216,549 | $2,134,295 | $2,263,817 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-1,040,027 | $-2,156,629 | $-5,774,598 | $-2,493,805 |
| Net Interest Income | $-334,675 | $-491,023 | $-379,028 | $-195,436 |
| Interest Income | $158,709 | $77,702 | $96,570 | $153,100 |
| Normalized Income | $813,995 | $-2,144,470 | $-6,056,650 | $-2,501,116 |
| Net Income From Continuing And Discontinued Operation | $-1,040,027 | $-2,156,629 | $-5,774,598 | $-2,493,805 |
| Total Operating Income As Reported | $1,649,305 | $-1,640,159 | $-5,748,078 | $-2,298,943 |
| Net Income Common Stockholders | $-1,040,027 | $-2,156,629 | $-5,774,598 | $-2,493,805 |
| Net Income | $-1,040,027 | $-2,156,629 | $-5,774,598 | $-2,493,805 |
| Net Income Including Noncontrolling Interests | $-1,040,027 | $-2,156,629 | $-5,774,598 | $-2,493,805 |
| Net Income Continuous Operations | $-1,040,027 | $-2,156,629 | $-5,774,598 | $-2,493,805 |
| Pretax Income | $-1,028,457 | $-2,146,573 | $-5,769,971 | $-2,486,133 |
| Special Income Charges | $-2,346,863 | $-15,391 | $357,028 | $7,334 |
| Interest Income Non Operating | $158,709 | $77,702 | $96,570 | $153,100 |
| Operating Income | $1,649,305 | $-1,640,159 | $-5,748,078 | $-2,298,943 |
| Gross Profit | $11,445,203 | $7,941,044 | $3,869,284 | $7,648,779 |
| Per Share | ||||
| Diluted EPS | $-0.12 | $-0.26 | $-0.75 | $-0.32 |
| Basic EPS | $-0.12 | $-0.26 | $-0.75 | $-0.32 |
| Other | ||||
| Tax Effect Of Unusual Items | $-492,841 | $-3,232 | $74,976 | $23 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $4,487,043 | $1,082,058 | $-2,957,019 | $342,652 |
| Total Unusual Items | $-2,346,863 | $-15,391 | $357,028 | $7,334 |
| Total Unusual Items Excluding Goodwill | $-2,346,863 | $-15,391 | $357,028 | $7,334 |
| Reconciled Depreciation | $2,729,601 | $2,687,181 | $2,717,001 | $2,487,583 |
| EBITDA (Bullshit earnings) | $2,140,180 | $1,066,667 | $-2,599,991 | $349,986 |
| EBIT | $-589,421 | $-1,620,514 | $-5,316,992 | $-2,137,597 |
| Diluted Average Shares | $9,026,000 | $8,167,000 | $7,748,000 | $7,745,000 |
| Basic Average Shares | $9,026,000 | $8,167,000 | $7,748,000 | $7,745,000 |
| Diluted NI Availto Com Stockholders | $-1,040,027 | $-2,156,629 | $-5,774,598 | $-2,493,805 |
| Tax Provision | $11,570 | $10,056 | $4,627 | $7,672 |
| Gain On Sale Of Ppe | $-106,350 | $-15,391 | $-8,099 | $7,334 |
| Other Special Charges | $-426,587 | - | $-365,127 | - |
| Impairment Of Capital Assets | $2,667,100 | - | - | - |
| Research And Development | $3,041,880 | $3,898,582 | $4,394,852 | $4,493,872 |
| Selling General And Administration | $6,754,018 | $5,682,621 | $5,222,510 | $5,453,850 |
| Other Gand A | $3,200,643 | $2,216,549 | $2,134,295 | $2,263,817 |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $26,959,923 | $27,403,526 | $24,859,312 | $30,227,180 |
| Total Assets | $42,532,447 | $45,100,477 | $43,808,102 | $44,860,649 |
| Total Non Current Assets | $25,587,565 | $30,057,727 | $32,338,252 | $30,865,893 |
| Other Non Current Assets | $37,686 | $33,368 | $57,655 | $76,628 |
| Goodwill And Other Intangible Assets | $95,557 | $114,661 | $133,765 | $152,869 |
| Current Assets | $16,944,882 | $15,042,750 | $11,469,850 | $13,994,756 |
| Prepaid Assets | $420,496 | $360,207 | $454,152 | $363,877 |
| Inventory | $9,267,369 | $7,112,623 | $7,811,841 | $6,038,539 |
| Receivables | $3,450,186 | $3,811,688 | $2,225,116 | $1,800,778 |
| Other Receivables | $31,177 | $40,555 | $39,733 | $42,178 |
| Accounts Receivable | $3,419,009 | $3,771,133 | $2,185,383 | $1,758,600 |
| Cash Cash Equivalents And Short Term Investments | $3,806,831 | $3,758,232 | $978,741 | $5,791,562 |
| Cash And Cash Equivalents | $3,806,831 | $3,758,232 | $978,741 | $5,791,562 |
| Other Intangible Assets | - | $19,104 | $38,208 | $57,312 |
| Debt | ||||
| Net Debt | $5,292,276 | $6,780,362 | $10,990,562 | $4,438,994 |
| Total Debt | $13,194,384 | $15,099,768 | $16,690,688 | $12,479,738 |
| Long Term Debt And Capital Lease Obligation | $11,498,710 | $13,170,077 | $14,617,605 | $11,408,527 |
| Long Term Debt | $7,488,922 | $9,040,975 | $10,540,496 | $9,191,109 |
| Current Debt And Capital Lease Obligation | $1,695,674 | $1,929,691 | $2,073,083 | $1,071,211 |
| Current Debt | $1,610,185 | $1,497,619 | $1,428,807 | $1,039,447 |
| Other Current Borrowings | $1,610,185 | $1,497,619 | $1,428,807 | $1,039,447 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $15,476,967 | $17,582,290 | $18,815,025 | $14,480,600 |
| Total Non Current Liabilities Net Minority Interest | $11,498,710 | $13,170,077 | $14,617,605 | $11,408,527 |
| Current Liabilities | $3,978,257 | $4,412,213 | $4,197,420 | $3,072,073 |
| Payables And Accrued Expenses | $2,282,583 | $2,482,522 | $2,124,337 | $2,000,862 |
| Payables | $802,980 | $949,452 | $890,784 | $794,887 |
| Total Tax Payable | $6,694 | $5,815 | $3,051 | $4,890 |
| Income Tax Payable | $6,694 | $5,815 | $3,051 | $4,890 |
| Accounts Payable | $796,286 | $943,637 | $887,733 | $789,997 |
| Equity | ||||
| Common Stock Equity | $27,055,480 | $27,518,187 | $24,993,077 | $30,380,049 |
| Total Equity Gross Minority Interest | $27,055,480 | $27,518,187 | $24,993,077 | $30,380,049 |
| Stockholders Equity | $27,055,480 | $27,518,187 | $24,993,077 | $30,380,049 |
| Retained Earnings | $-15,203,753 | $-14,163,726 | $-12,007,097 | $-6,232,499 |
| Other | ||||
| Treasury Shares Number | $59,771 | $63,301 | $63,301 | $67,301 |
| Ordinary Shares Number | $9,045,851 | $8,979,091 | $7,750,864 | $7,746,864 |
| Share Issued | $9,105,622 | $9,042,392 | $7,814,165 | $7,814,165 |
| Tangible Book Value | $26,959,923 | $27,403,526 | $24,859,312 | $30,227,180 |
| Invested Capital | $36,154,587 | $38,056,781 | $36,962,380 | $40,610,605 |
| Working Capital | $12,966,625 | $10,630,537 | $7,272,430 | $10,922,683 |
| Capital Lease Obligations | $4,095,277 | $4,561,174 | $4,721,385 | $2,249,182 |
| Total Capitalization | $34,544,402 | $36,559,162 | $35,533,573 | $39,571,158 |
| Treasury Stock | $130,760 | $138,482 | $138,482 | $147,233 |
| Additional Paid In Capital | $41,479,430 | $40,916,155 | $36,357,239 | $35,978,364 |
| Capital Stock | $910,563 | $904,240 | $781,417 | $781,417 |
| Common Stock | $910,563 | $904,240 | $781,417 | $781,417 |
| Long Term Capital Lease Obligation | $4,009,788 | $4,129,102 | $4,077,109 | $2,217,418 |
| Current Capital Lease Obligation | $85,489 | $432,072 | $644,276 | $31,764 |
| Current Accrued Expenses | $1,479,603 | $1,533,070 | $1,233,553 | $1,205,975 |
| Goodwill | $95,557 | $95,557 | $95,557 | $95,557 |
| Net PPE | $25,454,322 | $29,909,698 | $32,146,832 | $30,636,396 |
| Accumulated Depreciation | $-18,837,624 | $-21,041,551 | $-18,483,948 | $-15,875,620 |
| Gross PPE | $44,291,946 | $50,951,249 | $50,630,780 | $46,512,016 |
| Construction In Progress | $534,270 | $2,693,904 | $2,768,224 | $3,668,046 |
| Other Properties | $21,635,213 | $25,794,938 | $25,524,750 | $21,376,630 |
| Machinery Furniture Equipment | $702,838 | $1,056,145 | $1,036,374 | $900,306 |
| Buildings And Improvements | $20,902,758 | $20,889,395 | $20,784,565 | $20,050,167 |
| Land And Improvements | $516,867 | $516,867 | $516,867 | $516,867 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $1,867,702 | $9,530 | $402,619 | $149,855 |
| Work In Process | $5,748,889 | $5,746,865 | $5,815,194 | $3,468,702 |
| Raw Materials | $1,650,778 | $1,356,228 | $1,594,028 | $2,419,982 |
| Other Short Term Investments | - | - | - | - |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $1,224,853 | $-107,822 | $-6,566,749 | $-5,519,145 |
| Operating Activities | ||||
| Operating Cash Flow | $2,475,292 | $357,903 | $-4,674,236 | $-1,543,871 |
| Cash Flow From Continuing Operating Activities | $2,475,292 | $357,903 | $-4,674,236 | $-1,543,871 |
| Operating Gains Losses | $106,350 | $15,391 | $8,099 | $-7,334 |
| Investing Activities | ||||
| Capital Expenditure | $-1,250,439 | $-465,725 | $-1,892,513 | $-3,975,274 |
| Investing Cash Flow | $-1,214,307 | $-461,225 | $-1,890,039 | $-3,964,274 |
| Cash Flow From Continuing Investing Activities | $-1,214,307 | $-461,225 | $-1,890,039 | $-3,964,274 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $349,326 | $4,648,022 | $0 | $0 |
| Financing Cash Flow | $-1,212,386 | $2,882,813 | $1,751,454 | $1,114,239 |
| Cash Flow From Continuing Financing Activities | $-1,212,386 | $2,882,813 | $1,751,454 | $1,114,239 |
| Net Other Financing Charges | $-82,513 | $-296,871 | $-81,532 | $-19,306 |
| Net Common Stock Issuance | $349,326 | $4,648,022 | $0 | $0 |
| Common Stock Issuance | $349,326 | $4,648,022 | $0 | $0 |
| Other | ||||
| Repayment Of Debt | $-2,280,469 | $-1,468,338 | $-3,185,774 | $-897,125 |
| Issuance Of Debt | $801,267 | $0 | $5,000,000 | $2,000,000 |
| Interest Paid Supplemental Data | $443,019 | $528,907 | $444,954 | $338,516 |
| Income Tax Paid Supplemental Data | $10,691 | $7,293 | $6,466 | $4,923 |
| End Cash Position | $3,806,831 | $3,758,232 | $978,741 | $5,791,562 |
| Beginning Cash Position | $3,758,232 | $978,741 | $5,791,562 | $10,185,468 |
| Changes In Cash | $48,599 | $2,779,491 | $-4,812,821 | $-4,393,906 |
| Proceeds From Stock Option Exercised | $3 | $0 | $18,760 | $30,670 |
| Net Issuance Payments Of Debt | $-1,479,202 | $-1,468,338 | $1,814,226 | $1,102,875 |
| Net Long Term Debt Issuance | $-1,479,202 | $-1,468,338 | $1,814,226 | $1,102,875 |
| Long Term Debt Payments | $-2,280,469 | $-1,468,338 | $-3,185,774 | $-897,125 |
| Long Term Debt Issuance | $801,267 | $0 | $5,000,000 | $2,000,000 |
| Net PPE Purchase And Sale | $-1,214,307 | $-461,225 | $-1,890,039 | $-3,964,274 |
| Sale Of PPE | $36,132 | $4,500 | $2,474 | $11,000 |
| Purchase Of PPE | $-1,250,439 | $-465,725 | $-1,892,513 | $-3,975,274 |
| Change In Working Capital | $-2,053,105 | $-406,516 | $-2,111,947 | $-1,832,693 |
| Change In Other Current Assets | $-4,318 | $24,287 | $18,973 | $-50,513 |
| Change In Payables And Accrued Expense | $-195,254 | $362,606 | $156,995 | $341,614 |
| Change In Prepaid Assets | $-50,911 | $93,123 | $-87,830 | $-110,858 |
| Change In Inventory | $-2,154,746 | $699,218 | $-1,773,302 | $-2,948,565 |
| Change In Receivables | $352,124 | $-1,585,750 | $-426,783 | $935,629 |
| Changes In Account Receivables | $352,124 | $-1,585,750 | $-426,783 | $935,629 |
| Other Non Cash Items | $2,436,602 | $-107,075 | $118,343 | $36,134 |
| Stock Based Compensation | $295,871 | $325,551 | $368,866 | $266,244 |
| Depreciation Amortization Depletion | $2,729,601 | $2,687,181 | $2,717,001 | $2,487,583 |
| Depreciation And Amortization | $2,729,601 | $2,687,181 | $2,717,001 | $2,487,583 |
| Amortization Cash Flow | $19,104 | $19,104 | $19,104 | $19,104 |
| Amortization Of Intangibles | $19,104 | $19,104 | $19,104 | $19,104 |
| Depreciation | $2,710,497 | $2,668,077 | $2,697,897 | $2,468,479 |
| Gain Loss On Sale Of PPE | $106,350 | $15,391 | $8,099 | $-7,334 |
| Net Income From Continuing Operations | $-1,040,027 | $-2,156,629 | $-5,774,598 | $-2,493,805 |
| Net Short Term Debt Issuance | - | - | $0 | $0 |
| Short Term Debt Payments | - | - | $-2,000,000 | $0 |
| Short Term Debt Issuance | - | - | $2,000,000 | $0 |
| Net Investment Purchase And Sale | - | - | - | $0 |
| Sale Of Investment | - | - | - | $0 |
| Purchase Of Investment | - | - | - | - |
| Deferred Tax | - | - | - | - |
| Deferred Income Tax | - | - | - | - |
Fetched: 2026-06-23